Evidence map›Paper›PMID 34101541›Full record

ArticleAmerican journal of respiratory cell and molecular biology2021

Heterogeneity in Human Induced Pluripotent Stem Cell-derived Alveolar Epithelial Type II Cells Revealed with ABCA3/SFTPC Reporters.

Yuliang L Sun, Killian Hurley, Carlos Villacorta-Martin, Jessie Huang, Anne Hinds, Krithi Gopalan, Ignacio S Caballero, Scott J Russo, Joseph A Kitzmiller, Jeffrey A Whitsett and 2 more

Open access · greenAbstract read
In one paragraph

Article in American journal of respiratory cell and molecular biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. The transcriptional landscape of developing human trisomy 21 lungs.American journal of respiratory cell and molecular biology · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. HumanTissue barriers · 2024
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Yuliang L SunCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, Massachusetts.
Killian HurleyCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, Massachusetts.
Carlos Villacorta-MartinCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, Massachusetts.
Jessie HuangCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, Massachusetts.
Anne HindsThe Pulmonary Center and Department of Medicine, Boston University School of Medicine, Boston, Massachusetts.
Krithi GopalanCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, Massachusetts.
Ignacio S CaballeroCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, Massachusetts.
Scott J RussoPenn Center for Pulmonary Biology, University of Pennsylvania, Philadelphia, Pennsylvania; and.
Joseph A KitzmillerDivision of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Jeffrey A WhitsettDivision of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Michael F BeersPenn Center for Pulmonary Biology, University of Pennsylvania, Philadelphia, Pennsylvania; and.
Darrell N KottonCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, Massachusetts.
Boston Medical Center · USBoston University · USCincinnati Children's Hospital Medical Center · USPenn Center for AIDS Research · USRoyal College of Surgeons in Ireland · IE

Funding

Editing Alveolar Progenitor Cells for Correction of Monogenic DiseaseU01HL134745 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI KOTTON, DARRELL N., MORRISEY, EDWARD E · 2016 to 2022
$8.3M
Derivation of Transplantable Lung Epithelial Progenitors from iPS CellsR01HL095993 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Darrell N. Kotton · 2009 to 2026
$7.5M
Alveolar Epithelial Cell Dysfunction in Pulmonary Fibrosis: Leveraging SFTPC Mutations for Discovery of Molecular and Cellular TargetsR01HL145408 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MICHAEL FRANCIS BEERS · 2019 to 2026
$4.6M
A National iPS Cell Network with Deep Phenotyping for Translational ResearchU01TR001810 · NCATS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI GILAD, YOAV, KOTTON, DARRELL N. · 2016 to 2020
$4.4M
NRSA Training CoreTL1TR001410 · NCATS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI KOTTON, DARRELL N. · 2015 to 2024
$4.3M
NATIONAL BIOREPOSITORY OF LUNG DISEASE-SPECIFIC HUMAN INDUCED PLURIPOTENT STEM CELLS:THE PURPOSE OF THIS RESOURCE IS TO BUILD AND SUPPORT A CRITICAL75N92020C00005 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI N/A, N/A · 2021 to 2024
$2.6M
Generation of functional lung stem cells from human iPSCsU01HL148692 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Finn Hawkins, Darrell N. Kotton · 2019 to 2026
$2.0M
Modeling childhood interstitial lung disease with patient-specific pluripotent stem cells carrying ABCA3 mutationsF30HL142169 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI SUN, YULIANG · 2018 to 2021
$201k
Surfactant Protein C Mutations and Interstitial Lung DiseaseI01BX001176 · VA · PHILADELPHIA VA MEDICAL CENTER · PI MICHAEL FRANCIS BEERS · 2012 to 2026
–
BLRD VA I01 BX001176NCATS NIH HHS TL1 TR001410NCATS NIH HHS U01 TR001810NHLBI NIH HHS 75N92020C00005NHLBI NIH HHS F30 HL142169NHLBI NIH HHS R01 HL095993NHLBI NIH HHS R01 HL145408NHLBI NIH HHS U01 HL134745NHLBI NIH HHS U01 HL148692
6 · The paper itself

Abstract

Alveolar epithelial type 2 cells (AEC2s), the facultative progenitors of lung alveoli, are typically identified through the use of the canonical markers, SFTPC and ABCA3. Self-renewing AEC2-like cells have been generated from human induced pluripotent stem cells (iPSCs) through the use of knock-in SFTPC fluorochrome reporters. However, developmentally, SFTPC expression onset begins in the fetal distal lung bud tip and thus is not specific to mature AEC2s. Furthermore, SFTPC reporters appear to identify only those iPSC-derived AEC2s (iAEC2s) expressing the highest SFTPC levels. Here, we generate an ABCA3 knock-in GFP fusion reporter (ABCA3:GFP) that enables the purification of iAEC2s while allowing visualization of lamellar bodies, organelles associated with AEC2 maturation. Using an SFTPC

Indexed as

Alveolar Epithelial CellsATP-Binding Cassette TransportersCell DifferentiationEpithelial CellsHumansInduced Pluripotent Stem CellsLungPulmonary AlveoliPulmonary Surfactant-Associated Protein CPulmonary Surfactant-Associated ProteinsABCA3 protein, humanATP-Binding Cassette TransportersPulmonary Surfactant-Associated Protein CPulmonary Surfactant-Associated ProteinsSFTPC protein, humanalveolar epithelial cellsATP binding cassette A3gene editinghuman pluripotent stem cellssurfactant

Identifiers

PMID34101541
PMCPMC8525201
OpenAlexW3167269525

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.